-
Hackathons Aren’t Just for Coders. We Can Use Them to Save Lives
With growing attention on medical technology “hackathons“—summits that bring together engineers, clinicians, entrepreneurs, and designers to develop innovative solutions to health problems—the conversation has turned to whether they are more hype than impact. After all, what can 250 people in a room for two days really do to solve challenges that experts over decades have been unable to address?
- Categories
- Health Care, Technology
-
Inside the tech hub movement: In-depth lessons from a global mobile entrepreneurship initiative
“The technology startup scene has grown from zero to hundred in the last three years”, aMobile Monday co-founder in Bangkok recently told us.
- Categories
- Health Care
-
OPINION: Did ‘Social Business’ Sink the Cardboard Bike?
It’s time to retire the term “social business.” Better to run a business that honors agreements and respects the dignity of employees and customers.
- Categories
- Health Care, Impact Assessment
-
GeneXpert’s benefits still not reaching patients
The Department of Health’s multi-million rand investment in an automated, rapid TB test is being short-changed by slow health systems, said researchers this week.
- Categories
- Health Care
-
Better child TB diagnosis on the horizon
Accurate diagnosis of tuberculosis among children is notoriously difficult because the bacteria causing the disease tend to be detectable in the sputum only of adults, and because the clinical symptoms used to diagnose TB in children are also present in other conditions.
- Categories
- Health Care
-
Bold Ideas for Big Shifts in Global Health: The Bill & Melinda Gates Foundation awards its Grand Challenges Explorations grants
The Bill & Melinda Gates Foundation made Grand Challenges Explorations grants – some for $100,000 for Phase I grants and others for $1 million for Phase II grants – to fund scientific work on unproven ideas that could solve major global health and development problems.
- Categories
- Health Care
-
Promising malaria vaccine looks to employ robots to mass produce its product
Imagine that, in the face of substantial technical odds, you developed a vaccine for malaria that, in early trials, was 100 percent effective. But then, due to political wrangling over the budget, you couldn’t get the funding you needed to produce enough of the vaccine to market it. What would you do?
- Categories
- Health Care
-
Merck’s Expansion Plans in Africa And its Continental Outlook
Dr Karl-Ludwig Kley, Merck CEO and Chairman of Executive board is a man who believes in Africa and says Merck is in the continent to stay. Read on as he talks to Africa Science News
- Categories
- Health Care, Impact Assessment
Subscribe to Our 'Business in Global Development' Newsletter!
Our new weekly LinkedIn newsletter features NextBillion's latest original articles, along with curated news, jobs, bizdev opportunities and events from our recent coverage of impact-focused business in emerging markets.
We respect your privacy. Your information is safe and will never be shared.
Don't miss out. Subscribe today.